Boehringer Ingelheim International GmbH - Company Profile
Powered by 
All the data and insights you need on Boehringer Ingelheim International GmbH in one report.
$295
- Save hours of research time and resources with
our up-to-date Boehringer Ingelheim International GmbH Strategy Report
- Understand Boehringer Ingelheim International GmbH position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.
Headquarters
Germany
Address
Binger Strasse 173, Ingelheim am Rhein, Rheinland-Pfalz, 55216
Website
www.boehringer-ingelheim.com
Telephone
49 6132 770
No of Employees
51,944
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$25.4B
Boehringer Ingelheim International GmbH premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Human Pharmaceuticals: | Contract Manufacturing | Spiriva |
| Prescription Medicine | Spiriva Handihaler | |
| Cardiometabolic Diseases | Spiriva Respimat | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company announced the acquisition of T3 Pharmaceuticals AG. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with local innovative biopharmaceutical companies to launch of AmBio's strategic layout of accelerating the implementation of R&D innovation with the help of the international CDMO platform. |
| 2023 | Contracts/Agreements | In October, the company announced a companion diagnostic (CDx) partnership with Thermo Fisher Scientific to develop CDx tests to help identify patients with non-small cell lung cancer (NSCLC) with specific genomic mutations. |
Competitor Comparison
| Key Parameters | Boehringer Ingelheim International GmbH | Pfizer Inc | F. Hoffmann-La Roche Ltd | AbbVie Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | Switzerland | United States of America | Switzerland |
| City | Ingelheim am Rhein | New York | Basel | North Chicago | Basel |
| State/Province | Rheinland-Pfalz | New York | - | Illinois | - |
| No. of Employees | 51,944 | 83,000 | 103,613 | 50,000 | 103,000 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Hubertus von Baumbach | Chairman | Executive Board | - | - |
| Jean Scheftsik de Szolnok | Director - Animal Health Business Unit | Senior Management | 2020 | 58 |
| Matthias Reinig | Head - Group Communications | Senior Management | - | - |
| Michael Schmelmer | Director - Finance & Group Functions | Senior Management | 2019 | 57 |
| Carinne Knoche-Brouillon | Director - Human Pharma Business Unit | Senior Management | 2020 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward